Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65


Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet.

Ngeow J, Eng C.

NPJ Genom Med. 2016 Jan 13;1:15006. doi: 10.1038/npjgenmed.2015.6. eCollection 2016.


Predictive model for high-frequency microsatellite instability in colorectal cancer patients over 50 years of age.

Fujiyoshi K, Yamaguchi T, Kakuta M, Takahashi A, Arai Y, Yamada M, Yamamoto G, Ohde S, Takao M, Horiguchi SI, Natsume S, Kazama S, Nishizawa Y, Nishimura Y, Akagi Y, Sakamoto H, Akagi K.

Cancer Med. 2017 Jun;6(6):1255-1263. doi: 10.1002/cam4.1088. Epub 2017 May 23.


Screening for mismatch repair deficiency in colorectal cancer: data from three academic medical centers.

O'Kane GM, Ryan É, McVeigh TP, Creavin B, Hyland JM, O'Donoghue DP, Keegan D, Geraghty R, Flannery D, Nolan C, Donovan E, Mehigan BJ, McCormick P, Muldoon C, Farrell M, Shields C, Mulligan N, Kennedy MJ, Green AJ, Winter DC, MacMathuna P, Sheahan K, Gallagher DJ.

Cancer Med. 2017 Jun;6(6):1465-1472. doi: 10.1002/cam4.1025. Epub 2017 May 3.


Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.

D'Andrea E, Marzuillo C, De Vito C, Di Marco M, Pitini E, Vacchio MR, Villari P.

Genet Med. 2016 Dec;18(12):1171-1180. doi: 10.1038/gim.2016.29. Epub 2016 Apr 14. Review.


Management strategies in Lynch syndrome and familial adenomatous polyposis: a national healthcare survey in Japan.

Yamano T, Hamanaka M, Babaya A, Kimura K, Kobayashi M, Fukumoto M, Tsukamoto K, Noda M, Matsubara N, Tomita N, Sugihara K.

Cancer Sci. 2017 Feb;108(2):243-249. doi: 10.1111/cas.13123. Erratum in: Cancer Sci. 2017 Apr;108(4):804.


Epidemiology matters: peering inside the "black box" in economic evaluations of genetic testing.

Grosse SD, Khoury MJ.

Genet Med. 2016 Oct;18(10):963-5. doi: 10.1038/gim.2016.121. Epub 2016 Sep 8. No abstract available.


Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan.

Chen YE, Kao SS, Chung RH.

PLoS One. 2016 Aug 2;11(8):e0160599. doi: 10.1371/journal.pone.0160599. eCollection 2016.


Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.

Buchanan DD, Clendenning M, Rosty C, Eriksen SV, Walsh MD, Walters RJ, Thibodeau SN, Stewart J, Preston S, Win AK, Flander L, Ouakrim DA, Macrae FA, Boussioutas A, Winship IM, Giles GG, Hopper JL, Southey MC, English D, Jenkins MA.

J Gastroenterol Hepatol. 2017 Feb;32(2):427-438. doi: 10.1111/jgh.13468.


Hereditary cancer registries improve the care of patients with a genetic predisposition to cancer: contributions from the Dutch Lynch syndrome registry.

Vasen HF, Velthuizen ME, Kleibeuker JH, Menko FH, Nagengast FM, Cats A, van der Meulen-de Jong AE, Breuning MH, Roukema AJ, van Leeuwen-Cornelisse I, de Vos Tot Nederveen Cappel WH, Wijnen JT.

Fam Cancer. 2016 Jul;15(3):429-35. doi: 10.1007/s10689-016-9897-1.


Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond.

Hall MJ, Obeid EI, Schwartz SC, Mantia-Smaldone G, Forman AD, Daly MB.

Gynecol Oncol. 2016 Mar;140(3):565-74. doi: 10.1016/j.ygyno.2016.01.019. Epub 2016 Jan 23. Review.


Initiation of universal tumor screening for Lynch syndrome in colorectal cancer patients as a model for the implementation of genetic information into clinical oncology practice.

Cohen SA, Laurino M, Bowen DJ, Upton MP, Pritchard C, Hisama F, Jarvik G, Fichera A, Sjoding B, Bennett RL, Naylor L, Jacobson A, Burke W, Grady WM.

Cancer. 2016 Feb 1;122(3):393-401. doi: 10.1002/cncr.29758. Epub 2015 Oct 19.


A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers.

Oosterhoff M, van der Maas ME, Steuten LM.

Appl Health Econ Health Policy. 2016 Feb;14(1):51-65. doi: 10.1007/s40258-015-0198-x. Review.


Deficient mismatch repair: Read all about it (Review).

Richman S.

Int J Oncol. 2015 Oct;47(4):1189-202. doi: 10.3892/ijo.2015.3119. Epub 2015 Aug 12. Review.


Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers.

Hunter JE, Zepp JM, Gilmore MJ, Davis JV, Esterberg EJ, Muessig KR, Peterson SK, Syngal S, Acheson LS, Wiesner GL, Reiss JA, Goddard KA.

Cancer. 2015 Sep 15;121(18):3281-9. doi: 10.1002/cncr.29470. Epub 2015 Jun 2.


The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates.

Grosse SD, Palomaki GE, Mvundura M, Hampel H.

Genet Med. 2015 Jun;17(6):510-1. doi: 10.1038/gim.2015.53. No abstract available.


Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review.

Douglas MP, Ladabaum U, Pletcher MJ, Marshall DA, Phillips KA.

Genet Med. 2016 Feb;18(2):111-6. doi: 10.1038/gim.2015.69. Epub 2015 May 21. Review.


Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.

Gallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola LM, Horike-Pyne M, Hisama FM, Pritchard CC, Grady WM, Burke W, Jarvik GP, Veenstra DL.

J Clin Oncol. 2015 Jun 20;33(18):2084-91. doi: 10.1200/JCO.2014.59.3665. Epub 2015 May 4.


A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients.

Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C.

BMC Cancer. 2015 Apr 25;15:313. doi: 10.1186/s12885-015-1254-5.


Stakeholder perspectives on implementing a universal Lynch syndrome screening program: a qualitative study of early barriers and facilitators.

Schneider JL, Davis J, Kauffman TL, Reiss JA, McGinley C, Arnold K, Zepp J, Gilmore M, Muessig KR, Syngal S, Acheson L, Wiesner GL, Peterson SK, Goddard KA.

Genet Med. 2016 Feb;18(2):152-61. doi: 10.1038/gim.2015.43. Epub 2015 Apr 16.

Supplemental Content

Support Center